exosomes
(3)
Suchul Jang
He spent a decade engineering tiny vesicles to smuggle drugs where they were needed. Now he is running the American arm of a Korean biotech that wants the brain to clean up after itself - quietly, without the inflammation that has shadowed Alzheimer's drugs for years.
Phillip Maderia
Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.
Tom Benson
Tom Benson is the founder and CEO of Mitrix Bio, a Pleasanton, California biotech building toward whole-body mitochondrial transplantation. A serial software, hardware, and science entrepreneur, he managed the Linac Coherent Light Source femtosecond X-ray laser at Stanford's SLAC before turning his attention to the cell's power plants. His pitch is audacious and specific: grow young mitochondria from a person's own stem cells in a bioreactor, then transfuse them back to restore cellular energy and push the human lifespan toward 130 years.